S1B 3006
Alternative Names: S1B0-3006; S1B3006Latest Information Update: 31 Mar 2025
At a glance
- Originator S1 Biopharma
- Class
- Mechanism of Action Central nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sexual function disorders
Most Recent Events
- 19 Mar 2025 Preclinical trials in Sexual function disorders in USA (unspecified route), before March 2025 (S1 Biopharma pipeline, March 2025)